Biofrontera Accounts Payable vs Net Working Capital Analysis
| BFRI Stock | USD 0.99 0.03 2.94% |
Biofrontera financial indicator trend analysis is way more than just evaluating Biofrontera prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Biofrontera is a good investment. Please check the relationship between Biofrontera Accounts Payable and its Net Working Capital accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biofrontera. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more detail on how to invest in Biofrontera Stock please use our How to Invest in Biofrontera guide.
Accounts Payable vs Net Working Capital
Accounts Payable vs Net Working Capital Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Biofrontera Accounts Payable account and Net Working Capital. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Biofrontera's Accounts Payable and Net Working Capital is -0.5. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Net Working Capital in the same time period over historical financial statements of Biofrontera, assuming nothing else is changed. The correlation between historical values of Biofrontera's Accounts Payable and Net Working Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Biofrontera are associated (or correlated) with its Net Working Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Working Capital has no effect on the direction of Accounts Payable i.e., Biofrontera's Accounts Payable and Net Working Capital go up and down completely randomly.
Correlation Coefficient | -0.5 |
| Relationship Direction | Negative |
| Relationship Strength | Very Weak |
Accounts Payable
An accounting item on the balance sheet that represents Biofrontera obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Biofrontera are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Net Working Capital
Most indicators from Biofrontera's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Biofrontera current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biofrontera. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more detail on how to invest in Biofrontera Stock please use our How to Invest in Biofrontera guide.As of now, Biofrontera's Tax Provision is increasing as compared to previous years. The Biofrontera's current Issuance Of Capital Stock is estimated to increase to about 8.8 M, while Selling General Administrative is projected to decrease to under 34.7 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 540K | 1.2M | 1.1M | 1.5M | Interest Income | 16K | 175K | 168K | 90.6K |
Biofrontera fundamental ratios Correlations
Click cells to compare fundamentals
Biofrontera Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Currently Active Assets on Macroaxis
When determining whether Biofrontera offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biofrontera's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biofrontera Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biofrontera Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biofrontera. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more detail on how to invest in Biofrontera Stock please use our How to Invest in Biofrontera guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biofrontera. If investors know Biofrontera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biofrontera listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.16 | Revenue Per Share 11.573 | Quarterly Revenue Growth 0.34 | Return On Assets (0.40) | Return On Equity (1.49) |
The market value of Biofrontera is measured differently than its book value, which is the value of Biofrontera that is recorded on the company's balance sheet. Investors also form their own opinion of Biofrontera's value that differs from its market value or its book value, called intrinsic value, which is Biofrontera's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biofrontera's market value can be influenced by many factors that don't directly affect Biofrontera's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biofrontera's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biofrontera is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biofrontera's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.